Oncimmune is a leading early cancer detection company. It has pioneered the development of autoantibody assay technologies that have the potential to allow cancer detection up to four years earlier than other methods and be applied to a wide range of solid tumour types. In 2009, Oncimmune launched its proprietary platform technology for early cancer detection, called EarlyCDT®. The first test, EarlyCDT®-Lung, was commercialised in 2009 and test marketed until 2012, at which time it launched nationally across the US and since over 125,000 commercial tests have been sold. It is now available through physicians in the US and also privately in the UK and other regions. EarlyCDT®-Lung is a simple blood test which is ordered by a doctor to aid in the risk assessment and early detection of lung cancer in high-risk patients and to stratify indeterminate pulmonary nodules for the risk of malignancy. Oncimmune Ltd is headquartered in Nottingham, UK and testing is conducted in our CLIA-approved laboratory, based in Kansas City, USA.
Company Growth (employees)
Nottingham, GB
Size (employees)
34 (est)
Oncimmune was founded in 2006 and is headquartered in Nottingham, GB

Oncimmune Office Locations

Oncimmune has offices in Nottingham and De Soto
Nottingham, GB (HQ)
Hucknall Rd
De Soto, US
8960 Commerce Dr
Show all (2)

Oncimmune Financials and Metrics

Summary Metrics

Founding Date


Total Funding

$15 m

Latest funding size

$15 m

Time since last funding

about 1 year


Oncimmune's latest funding round in January 2017 was reported to be $15 m. In total, Oncimmune has raised $15 m

Oncimmune Financials

Oncimmune's revenue was reported to be £80 k in FY, 2017 which is a 74% decrease from the previous period.

Revenue (FY, 2017)

80 k

Gross profit (FY, 2017)

(168 k)

Gross profit margin (FY, 2017), %


Net income (FY, 2017)

(4 m)

EBITDA (FY, 2017)

(3.3 m)

EBIT (FY, 2017)

(3.3 m)

Cash (31-May-2017)

4.9 m
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017


15.4 k55 k149.4 k1.5 m1.1 m1.3 m303 k80 k

Revenue growth, %


Cost of goods sold

136.3 k140.5 k2.9 k248 k

Gross profit

1.4 m916.4 k1.3 m(168 k)
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017


3.3 m3 m3.7 m5.3 m2.7 m2.1 m1.1 m1.6 m1.3 m10.1 m4.9 m

Accounts Receivable

334.1 k118.8 k265.4 k28 k16 k


116.1 k91 k

Current Assets

3.4 m3.2 m3.8 m6.4 m2.8 m2.3 m1.9 m2.4 m1.9 m10.5 m5.1 m
    GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

    Net Income

    (2.6 m)(3.9 m)(6.6 m)(6.1 m)(4.3 m)(4.4 m)(3 m)(1.4 m)(2 m)(1.8 m)(4 m)

    Cash From Operating Activities

    (3.4 m)(5.3 m)(4.7 m)(4.5 m)(4.1 m)(3.2 m)(2.3 m)(1.4 m)

    Cash From Financing Activities

    3.6 m5.5 m5.9 m1.6 m3.5 m2 m1.8 m1.2 m

    Net Change in Cash

    (348.2 k)439.7 k1.6 m(2.6 m)(534.9 k)(1.1 m)557.5 k(310.3 k)
      GBPY, 2017


      2.6 k

      Financial Leverage

      -0.7 x
      Show all financial metrics

      Oncimmune's Web-traffic and Trends

      Oncimmune Online and Social Media Presence

      Oncimmune Company Life and Culture

      You may also be interested in